Form 4: Calix CEO Sells Shares After Option Exercise
Insider Transaction Report
Calix President & CEO Michael Weening executed options and sold a significant number of common shares in late October and early November 2025, pursuant to a Rule 10b5-1 trading plan.
Summary
- Michael Weening, President & CEO and Director of Calix, Inc. (CALX), reported transactions involving the company's common stock.
- On October 30, 2025, Mr. Weening acquired 200,000 shares of common stock through the exercise of stock options at an exercise price of $7.84 per share.
- On the same date, he disposed of 150,000 shares at a weighted average sale price of $64.628 per share (ranging from $64.55 to $65.00) and an additional 50,000 shares at a weighted average sale price of $67.5456 per share (ranging from $67.35 to $67.93).
- On November 3, 2025, Mr. Weening acquired another 74,000 shares of common stock through the exercise of stock options at an exercise price of $7.84 per share.
- Also on November 3, 2025, he disposed of 74,000 shares at a weighted average sale price of $67.4203 per share (ranging from $66.245 to $69.450).
- All sales were conducted pursuant to a Rule 10b5-1 trading plan adopted on February 28, 2025.
- Following these transactions, Mr. Weening directly beneficially owns 16,117 shares of Calix common stock.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. While insider selling can sometimes be viewed negatively, these transactions were pre-planned under a 10b5-1 plan, mitigating concerns about immediate negative sentiment. The high sale price relative to the exercise price is a positive for the executive.
Positives
- The transactions were executed at significantly higher market prices ($64.628 to $67.5456 per share) compared to the option exercise price ($7.84 per share), indicating a substantial gain for the insider.
- The sales were conducted under a pre-arranged Rule 10b5-1 trading plan, which suggests a systematic approach to managing personal holdings rather than a reaction to immediate company news.
Negatives
- The President & CEO sold a substantial number of shares (274,000 shares in total) over a short period, which could be interpreted by some investors as a lack of confidence, despite the 10b5-1 plan.
Future Outlook
This Form 4 filing does not contain forward-looking statements or guidance regarding the company's future performance or outlook.
Industry Context
This filing reports an individual insider transaction and does not provide broader industry context or trends. It reflects a personal financial decision by a key executive.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Trading Plan Adoption | The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted on February 28, 2025. This plan allows insiders to set up a pre-scheduled plan to buy or sell company stock, providing an affirmative defense against insider trading allegations. | 02/28/2025 | Enhances transparency and reduces the perception of opportunistic trading by company insiders, aligning with good corporate governance practices. |
Stakeholder Impact
- Shareholders: May observe the CEO's sale of a significant number of shares. The existence of a 10b5-1 plan may alleviate concerns that the sale is based on undisclosed negative information, but some may still view it as a reduction in management's direct equity exposure.
- Employees: No direct impact mentioned, but general sentiment around executive stock sales can sometimes influence employee morale.
Key Dates
| Date | Description |
|---|---|
| 11/27/2023 | Date when 100% of the shares subject to the option were fully vested and exercisable. |
| 02/28/2025 | Date when the Rule 10b5-1 trading plan was adopted. |
| 10/30/2025 | Date of option exercise for 200,000 shares and subsequent sale of 200,000 shares. |
| 11/03/2025 | Date of option exercise for 74,000 shares and subsequent sale of 74,000 shares. |
| 11/27/2029 | Expiration date of the exercised stock options. |
Keywords
Calix, CALX, Michael Weening, Insider Trading, Form 4, Stock Option Exercise, Share Sale, 10b5-1 Plan, CEO, Director
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.